Clinical Trial

UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases

Name: UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases — clinical trial record (NCT07155369)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Active, Not Recruiting

View on ClinicalTrials.gov →

Summary

This is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases.

Trial Details

NCT Number	NCT07155369
Lead Sponsor	The Affiliated Hospital of Xuzhou Medical University Collaborators: Shanghai Xiniao Biotech Co., Ltd.
Conditions	Systemic Lupus Erythematosus, Systemic Sclerosis
Enrollment	18 participants
Start Date	2025-03-18
Primary Completion	2026-09 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2025-09-04